• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. Pakistan Journal of Biological Sciences
  2. Vol 8 (12), 2005
  3. 1794-1797
  • Issues
    Online First Current Issue All Issues
  • Information About
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

Pakistan Journal of Biological Sciences

Year: 2005 | Volume: 8 | Issue: 12 | Page No.: 1794-1797
DOI: 10.3923/pjbs.2005.1794.1797
crossmark

Facebook Twitter Reddit Linkedin E-mail
Research Article

Mycobacterium Group: Identification and Sensitivities of Clinical Isolates Against First Line Drugs. I

Tanveer Khanum
Department of Microbiology,

Aliya Hayat
Department of Microbiology,

Ajaz Rasool
University of Karachi, Pakistan

Saleem Hafiz
STIJT (Sindh Institute of Urology and Transplantation)

Rafia Azmat
Department of Chemistry,

Rukhsana Talat
Department of Zoology

ABSTRACT


Mycobacterium infections play a very important role in the community especially in areas where the disease is endemic. Mycobacterial infections need to be treated with a mixture of agents to improve efficacy, to prevent resistant, or to overcome intrinsic resistant. In order to see the resistant pattern of the local isolates a prospective study was planned. About, 100 clinical isolates of mycobacterium were collected from local clinical laboratories they were confirmed by standard tests recommended by ASM manual and sensitivities were set up by resistant ratio method against the first line drugs, i.e., Streptomycin, Isoniazid, Ethambutanol Rifampicin. and Bac 201 was also found to have antimycobacterial activity. Over all 38% were Mycobacterium tuberculosis, 22% Mycobacterium xenopi, 16% Mycobacterium kansasai and 12% Mycobacterium thermoresistible 4% Mycobacterium merinum, 4% Mycobacterium fortutum and 4% Mycobacterium terraecomplex 70% were found to be slow grower, while 28% were fast grower and 2% were found to be moderate grower 22% were Photochromogen and 12% were Scotochromogen, 64% were non chromogenic. About 62% were atypical mycobacteria. Resistance pattern in this study was not very different from other studies. In this study highest resistance was to Rifampicin 30% followed by Isoniazid and Strptomycin 8%. Ethambutanol and Pyrazinamide were found to have relatively lower resistance 6 and 4% respectively. A protein antibiotic i.e., Staphylococcin Bac 201 was also tried which gave some interesting results, its known conc. i.e., 1218 AU mL-1. Sixty two percent were completely resistant to all 6 concs and 38% showed MIC as 1218 AU mL-1 , 25-64% resistant to first line drug has been observed. With the emergence of drug resistant mycobacteria it has become essential to carry out the drug susceptibility testing regularly.
PDF References Citation

Keywords


  • staphylococcin
  • first line drugs sensitivity
  • Mycobacterium sp.,

How to cite this article

Tanveer Khanum, Aliya Hayat, Ajaz Rasool, Saleem Hafiz, Rafia Azmat and Rukhsana Talat, 2005. Mycobacterium Group: Identification and Sensitivities of Clinical Isolates Against First Line Drugs. I. Pakistan Journal of Biological Sciences, 8: 1794-1797.

DOI: 10.3923/pjbs.2005.1794.1797

URL: https://scialert.net/abstract/?doi=pjbs.2005.1794.1797

REFERENCES


  1. Centers for Disease Control and Prevention, 1993. Initial therapy for tuberculosis in the era of multidrug resistance recommendations of the advisory council for the elimination of tuberculosis. Morb. Mortal. Wkly. Rep., 42: 1-8.

  2. Murray, P., E. Baron, J. Jorgensen, M. Pfaller and R. Yolken, 2003. Manual of Clinical Microbiology. 8th Edn., American Society for Microbiology, Washington, DC., USA., pp: 2113.
    Direct Link

  3. Dye, C., S. Scheele, P. Dolin, V. Pathania and M.C. Raviglione, 1999. Global burden of tuberculosis. JAMA, 282: 677-686.
    Direct Link

  4. Lewis, K., 1994. Multidrug resistance pumps in bacteria: Variations on a theme. Trends Biochem. Sci., 19: 119-123.
    CrossRefDirect Link

  5. Thierry, D., M.D. Cave, K.D. Eisenach, L.T. Crawford, J.H. Bates, B. Gicquel and J.L. Guesdon, 1990. Is 6110 an is like element of Mycobacterium tuberculosis complex. Nucleic Acids Res., 18: 188-188.

  6. Fang, Z., C. Doig, A. Rayner, D.T. Kenna, B. Watt and K.J. Forbes, 1999. Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland. J. Clin. Microbiol., 37: 998-1003.

  7. Wilson, S.M., 1993. New rapid phage based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nature Med., 364: 465-468.

  8. Iqbal, A., S.A. Ali, S. Ahmed and S.A. Rasool, 1999. Isolation and partial characterization of Bac201 a plasmid-associated bacteriocines-like inhibitory substance from Staphylococcus aureus AB201. J. Basic Microbiol., 39: 325-336.

  9. Bloom, B.R. and C.J.L. Murray, 1992. Tuberculosis commentary on a reemergence killer. Science, 257: 1055-1064.

  10. American Thoracic Society, 1997. Diagnosis and treatment of disease caused by non tuberculous 657-662 mycobacteria. Am. J. Respir. Crit. Care Med., 156: 1-25.

  11. Springer, B., L. Stockman, K. Teschner, G.D. Roberts and E.C. Bottger, 1996. Identification of mycobacteria molecular versus phenotypic methods. J. Clin. Microbiol., 34: 296-303.
    PubMed

  12. Small, P.M., P.C. Hopewell, S.P. Singh, A. Paz and J. Parsonnet et al., 1994. The epidemiology of tuberculosis in San Francisco a population based study using conventional and molecular methods. N. Eng. J. Med., 330: 1703-1709.
    Direct Link

  13. Pfyffer, G.E., B.A.B. Elliott and J.W. Jr. Richard, 2003. Mycobacterium General Characteristics Isolation and Staining Procedures. In: Manual of Clinical Microbiology, Murray, P.A. (Ed.). 8th Edn., American Society for Microbiology, Washington, D.C pp: 532-559.

  14. NCCLS., 2003. Susceptibility Testing of Mycobacteria Nocardia and Other Aerobic Actinomycetes Approved Standard. NCCLS, USA.

  15. Schmitt, H., N. Schnitzler, J. Riehl, G. Adam, H.G. Sieberth and G. Haase, 1999. Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin rifabutin and sparfloxacin. Clin. Infect. Dis., 29: 120-124.

  16. Runyon, E.H., 1959. Anonymous mycobacteria in pulmonary disease. Med. Clin. N. Am., 43: 273-273.

  17. Donnabella, V., J.S. Schicchi, S. Bonk, B. Hanna and WN. Rom, 2000. Increasing incidence of Mycobacterium xenopi at bellevue hospital an emerging pathogen or a product of improved laboratory methods. Chest, 118: 1365-1370.

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved